Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the United States Patent and Trademarks Office (USPTO) granted a US process patent for its novel stem-cell based drug Stempeucel.

Stempeucel will initially be used for the treatment of CLI and is a breakthrough treatment option which directly addresses the root cause of the disease, unlike other drugs which typically treat the symptoms and not the disease itself. 

Chandru Chawla, Head Cipla New Ventures said, "Through Cipla Group's investment in Stempeutics, we are demonstrating a firm commitment bringing the next generation of biologics in order to address unmet medical needs. With this novel Stempeucel technology, we are supporting Stempeutics discovery of this first-of-its-kind regenerative medicine." 

Shares of the Cipla declined Rs 5.9, or 0.81%, to settle at Rs 724.70. The total volume of shares traded was 193,377 at the BSE (Wednesday).